Compare NNI & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NNI | APLS |
|---|---|---|
| Founded | 1978 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 5.2B |
| IPO Year | 2003 | 2015 |
| Metric | NNI | APLS |
|---|---|---|
| Price | $143.70 | $40.95 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 21 |
| Target Price | ★ $140.00 | $33.59 |
| AVG Volume (30 Days) | 122.8K | ★ 8.8M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | ★ 134.86 | 112.50 |
| EPS | ★ 11.79 | 0.20 |
| Revenue | N/A | ★ $1,003,782,000.00 |
| Revenue This Year | $2.28 | N/A |
| Revenue Next Year | $5.38 | $18.19 |
| P/E Ratio | ★ $12.20 | $204.73 |
| Revenue Growth | N/A | ★ 28.46 |
| 52 Week Low | $105.12 | $16.10 |
| 52 Week High | $144.38 | $40.96 |
| Indicator | NNI | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 68.73 | 86.78 |
| Support Level | $128.24 | $19.29 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 3.17 | 0.08 |
| MACD | 0.71 | -0.66 |
| Stochastic Oscillator | 86.72 | 85.71 |
Nelnet Inc is a United States based company engaged in these four reportable segments; Loan Servicing and Systems focuses on student and consumer loan origination services and servicing, loan origination and servicing-related technology solutions, and outsourcing business services; Education Technology Services and Payments segment provides education services, payment technology, and community management solutions for K-12 schools, institutions, churches, and businesses; Asset Generation and Management segment includes the acquisition and management of student and other loan assets; and Nelnet Bank focuses on the private education and unsecured consumer loan markets. Maximum revenue for the company is generated from its Education Technology Services and Payments segment.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).